Vascular calcification (VC), which is categorized by intimal and medial calcification,
depending on the site (s) involved within the vessel, is closely related to cardiovascular …

Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney
disease (CKD). Both conditions are rising in incidence as well as prevalence, creating poor …

Cardiovascular disease is the main cause of early death in the settings of chronic kidney
disease (CKD), type 2 diabetes mellitus (T2DM), and ageing. Cardiovascular events can be …

Hypophosphatasia (HPP) results from ALPL mutations leading to deficient activity of the
tissue-non-specific alkaline phosphatase isozyme (TNAP) and thereby extracellular …

Alkaline phosphatase (ALP) is an evolutionary conserved enzyme and widely used
biomarker in clinical practice. Tissue-nonspecific alkaline phosphatase (TNALP) is one of …

Medial vascular calcification, associated with enhanced mortality in chronic kidney disease
(CKD), is fostered by osteo-/chondrogenic transdifferentiation of vascular smooth muscle …

Recent years have seen an increase in the number of studies focusing on alkaline
phosphatases (APs), revealing an expanding complexity of function of these enzymes. Of …

Background The high cardiovascular morbidity and mortality of patients with CKD may result
in large part from medial vascular calcification, a process promoted by hyperphosphatemia …

The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by
calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed …

Hypophosphatasia (HPP) is caused by loss‐of‐function mutation (s) of the gene that
encodes the tissue‐nonspecific isoenzyme of alkaline phosphatase (TNSALP). Autosomal …